BRPI0507271A - 2-(3-substituìda-aril)amino-4-aril-tiazóis como inibidores de tirosina cinase - Google Patents

2-(3-substituìda-aril)amino-4-aril-tiazóis como inibidores de tirosina cinase

Info

Publication number
BRPI0507271A
BRPI0507271A BRPI0507271-9A BRPI0507271A BRPI0507271A BR PI0507271 A BRPI0507271 A BR PI0507271A BR PI0507271 A BRPI0507271 A BR PI0507271A BR PI0507271 A BRPI0507271 A BR PI0507271A
Authority
BR
Brazil
Prior art keywords
aryl
amino
substituted
tyrosine kinase
kinase inhibitors
Prior art date
Application number
BRPI0507271-9A
Other languages
English (en)
Inventor
Alain Moussy
Marco Ciufolini
Camille Wermuth
Bruno Giethlen
Original Assignee
Ab Science
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ab Science filed Critical Ab Science
Publication of BRPI0507271A publication Critical patent/BRPI0507271A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Obesity (AREA)
  • Pulmonology (AREA)
  • Endocrinology (AREA)
  • Transplantation (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Emergency Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Communicable Diseases (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Cosmetics (AREA)

Abstract

2-(3-SUBSTITUíDA-ARIL)AMINO-4-ARIL-TIAZóIS COMO INIBIDORES DE TIROSINA CINASE. A presente invenção refere-se a novos compostos selecionados de 2-(3-substituída-aril)amino-4-aril-tiazóis que seletivamente modulam, regulam e/ou inibem a transdução sinal mediada por certas tirosinas cinases nativas e/ mutantes ou envolvidas em uma variedade de doenças animais e humanas tais como distúrbios degenerativos, alérgicos, metabólicos e de proliferação celular. Mais particularmente, estes compostos são inibidores de c-kit potentes e seletivos.
BRPI0507271-9A 2004-01-30 2005-01-28 2-(3-substituìda-aril)amino-4-aril-tiazóis como inibidores de tirosina cinase BRPI0507271A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US54006404P 2004-01-30 2004-01-30
PCT/IB2005/000401 WO2005073225A1 (en) 2004-01-30 2005-01-28 2-(3-substituted-aryl)amino-4-aryl-thiazoles as tyrosine kinase inhibitors

Publications (1)

Publication Number Publication Date
BRPI0507271A true BRPI0507271A (pt) 2007-06-26

Family

ID=34826177

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0507271-9A BRPI0507271A (pt) 2004-01-30 2005-01-28 2-(3-substituìda-aril)amino-4-aril-tiazóis como inibidores de tirosina cinase

Country Status (12)

Country Link
EP (1) EP1711497A1 (pt)
JP (1) JP2007519711A (pt)
KR (1) KR20060129413A (pt)
CN (1) CN1934107A (pt)
AU (1) AU2005209485A1 (pt)
BR (1) BRPI0507271A (pt)
CA (1) CA2554925A1 (pt)
IL (1) IL177007A0 (pt)
NO (1) NO20063861L (pt)
NZ (1) NZ548884A (pt)
WO (1) WO2005073225A1 (pt)
ZA (1) ZA200606152B (pt)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG159561A1 (en) 2005-05-09 2010-03-30 Achillion Pharmaceuticals Inc Thiazole compounds and methods of use
US20060281788A1 (en) 2005-06-10 2006-12-14 Baumann Christian A Synergistic modulation of flt3 kinase using a flt3 inhibitor and a farnesyl transferase inhibitor
EP2016070B1 (en) 2006-04-20 2016-01-13 Janssen Pharmaceutica N.V. Inhibitors of c-fms kinase
MX2008013533A (es) 2006-04-20 2009-01-15 Janssen Pharmaceutica Nv Compuestos heterociclicos como inhibidores de c-fms cinasa.
EP2397138B1 (en) * 2006-04-20 2013-12-11 Janssen Pharmaceutica NV Aromatic amide derivatives as C-KIT kinase inhibitors
US8697716B2 (en) 2006-04-20 2014-04-15 Janssen Pharmaceutica Nv Method of inhibiting C-KIT kinase
US7879856B2 (en) 2006-12-22 2011-02-01 Rigel Pharmaceuticals, Inc. Diaminothiazoles useful as Axl inhibitors
GB0701426D0 (en) * 2007-01-25 2007-03-07 Univ Sheffield Compounds and their use
US8183263B2 (en) 2007-05-22 2012-05-22 Achillion Pharmaceuticals, Inc. Heteroaryl substituted thiazoles
JO3240B1 (ar) 2007-10-17 2018-03-08 Janssen Pharmaceutica Nv c-fms مثبطات كيناز
WO2009114552A1 (en) * 2008-03-10 2009-09-17 The Board Of Trustees Of The Leland Stanford Junior University Heteroaryl compounds, compositions, and methods of use in cancer treatment
UA103319C2 (en) 2008-05-06 2013-10-10 Глаксосмитклайн Ллк Thiazole- and oxazole-benzene sulfonamide compounds
US8106209B2 (en) 2008-06-06 2012-01-31 Achillion Pharmaceuticals, Inc. Substituted aminothiazole prodrugs of compounds with anti-HCV activity
RU2555326C2 (ru) 2009-01-16 2015-07-10 Риджел Фармасьютикалз, Инк. ИНГИБИТОРЫ Axl ДЛЯ ПРИМЕНЕНИЯ В КОМБИНИРОВАННОЙ ТЕРАПИИ ДЛЯ ПРЕДОТВРАЩЕНИЯ, УСТРАНЕНИЯ ИЛИ ЛЕЧЕНИЯ МЕТАСТAЗИРУЮЩЕГО РАКА
AU2012288900B2 (en) * 2011-07-27 2016-10-06 Ab Science Selective protein kinase inhibitors
CN103130792B (zh) * 2011-11-30 2016-05-04 正大天晴药业集团股份有限公司 一种2-氨基噻唑类化合物
EP2869897A4 (en) * 2012-07-06 2016-09-28 Univ Duke ACTIVATION OF THE TRPV4 ION CHANNEL BY PHYSICAL STIMULI AND IMPORTANT ROLE FOR TRPV4 IN ORGANIC INFLAMMATION AND JUCKREIZ
CN104870454B (zh) 2012-08-07 2020-03-03 詹森药业有限公司 用于制备杂环酯衍生物的方法
CN107266405A (zh) 2012-08-07 2017-10-20 詹森药业有限公司 用于制备c‑fms激酶抑制剂的方法
CN103254184B (zh) * 2013-05-27 2015-03-18 湖南科技大学 5-取代-3-[5-羟基-4-吡喃酮-2-基-甲硫基]-4-氨基-1,2,4-三唑类化合物及其用途
CN103319467B (zh) * 2013-06-15 2015-10-14 湖南科技大学 一种4-[5-羟基-4-吡喃酮-2-基亚甲氨基]-3-巯基-1,2,4-三唑化合物及用途
WO2016028325A1 (en) 2014-08-22 2016-02-25 Duke University Trpa1 and trpv4 inhibitors and methods of using the same for organ-specific inflammation and itch
US11229628B2 (en) 2015-01-09 2022-01-25 Duke University TRPA1 and TRPV4 inhibitors and methods of using the same for organ-specific inflammation and itch
US11564911B2 (en) 2016-04-07 2023-01-31 Duke University Small molecule dual-inhibitors of TRPV4 and TRPA1 for sanitizing and anesthetizing
EP3942045A1 (en) 2019-03-21 2022-01-26 Onxeo A dbait molecule in combination with kinase inhibitor for the treatment of cancer
EP4054579A1 (en) 2019-11-08 2022-09-14 Institut National de la Santé et de la Recherche Médicale (INSERM) Methods for the treatment of cancers that have acquired resistance to kinase inhibitors
WO2021148581A1 (en) 2020-01-22 2021-07-29 Onxeo Novel dbait molecule and its use

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA66810C2 (uk) * 1997-10-27 2004-06-15 Агорон Фармацевтикалз Інк. Похідні 4-амінотіазолу та композиції на їх основі як інгібітори циклінозалежних кіназ
US6262096B1 (en) * 1997-11-12 2001-07-17 Bristol-Myers Squibb Company Aminothiazole inhibitors of cyclin dependent kinases
NZ513639A (en) * 1999-04-15 2004-02-27 Bristol Myers Squibb Co Cyclic protein tyrosine kinase inhibitors
HN2002000156A (es) * 2001-07-06 2003-11-27 Inc Agouron Pharmaceuticals Derivados de benzamida tiazol y composiciones farmaceuticas para inhibir la proliferacion de celulas y metodos para su utilización.
EA007717B1 (ru) * 2001-08-13 2006-12-29 Янссен Фармацевтика Н.В. 2-амино-4,5-тризамещенные производные тиазолила
CA2474322A1 (en) * 2002-01-25 2003-07-31 Kylix Pharmaceuticals B.V. 4(hetero-) aryl substituted (thia-/oxa-/pyra) zoles for inhibition of tie-2
DE60316810T2 (de) * 2002-08-02 2008-07-17 Ab Science 2-(3-aminoaryl)amino-4-aryl-thiazole und ihre verwendung als c-kit inhibitoren
AU2004251668B2 (en) * 2003-06-03 2008-03-20 Triad Therapeutics, Inc 5-membered heterocycle-based p-38 inhibitors

Also Published As

Publication number Publication date
JP2007519711A (ja) 2007-07-19
NZ548884A (en) 2010-06-25
KR20060129413A (ko) 2006-12-15
EP1711497A1 (en) 2006-10-18
CA2554925A1 (en) 2005-08-11
AU2005209485A1 (en) 2005-08-11
IL177007A0 (en) 2006-12-10
ZA200606152B (en) 2007-11-28
WO2005073225A1 (en) 2005-08-11
CN1934107A (zh) 2007-03-21
NO20063861L (no) 2006-10-23

Similar Documents

Publication Publication Date Title
ATE465731T1 (de) 2-aminoaryloxazol-verbindungen als tyrosinkinase- hemmer
MXPA05001277A (es) 2-(3-aminoaril)amino-4-aril-tiazoles y su uso como inhibidores del c-kit.
NO20063861L (no) 2-(3-substituert aryl)amin-4-arylthiazoler som tyrosinkinasehemmere
NO20091989L (no) Forbindelser som modulerer c-fms og/eller C-kit aktivitet og deres anvendelse
NO20075627L (no) Inhibitorer av cytosolisk fosfolipase A2
NO20075553L (no) Substituerte oxazolderivater og deres anvendelse som tyrosinkinaseinhibitorer
NO20075992L (no) Forbindelser som modulerer C-Kit og C-FMS aktivitet og anvendelser derav
TN2009000128A1 (en) Dihydropyridine derivatives useful as protein kinase inhibitors
MXPA05010711A (es) Compuestos y composiciones novedosos como inhibidores de proteina-quinasa.
TW200630360A (en) Polymorphs of {5-[3-(4,6-difluoro-1H-benzoimidazol-2-yl)-1H-indazol-5-yl]-4-methyl-pyridin-3-ylmethyl}-ethyl-amine
EA200900828A1 (ru) Соединения и композиции в качестве ингибиторов активности каннабиноидного рецептора 1
EA200970402A1 (ru) Триазолопиридазиновые модуляторы протеинкиназ
EP2592072A3 (en) Human protein tyrosine phosphatase inhibitors and their use
IL192557A (en) Imidazole derivatives are conserved and used as ptpase inhibitors
DE602004024374D1 (de) Zusammensetzungen zur verwendung als protein-kinase-inhibitoren
WO2006064375A2 (en) Aminoaryl substituted five-membered ring heterocyclic compounds for the treatment of diseases
DE602005014566D1 (de) Chinolinon-carboxamid-verbindungen
ATE547396T1 (de) Dicycloalkylcarbamoyl-harnstoffe als glucokinase- aktivatoren
JO2724B1 (en) 3-Alternative-5 -6-Amino Alkyl Indole-2-Carboxyl Acid Amide and Related Isotopes as Casein Kinase Inhibitors
EA200701867A1 (ru) Хинолиноновые соединения в качестве агонистов рецептора 5-ht
DE602005019090D1 (de) Pyrrolidin-2-on-Derivate zur Verwendung als DP1-Rezeptoragonisten
CU20070222A7 (es) Derivados de oxazol sustituidos y su uso como inhibidores de tirosina quinasa
UA93679C2 (en) Compounds modulating c-kit and c-fms activity and uses therefor
ATE540951T1 (de) Substituierte 7,8-dihydro-1h-pyrimidoä4,5- büdiazepin-4-amine als kinase inhibitoren

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 8A ANUIDADE, CONFORME ART. 10 DA RES. 124/06.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2204 DE 02/04/2013.